Acute Effects of Metformin and Vildagliptin after a Lipid-Rich Meal on Postprandial Microvascular Reactivity in Patients with Type 2 Diabetes and Obesity: A Randomized Trial

被引:5
|
作者
Schiappacassa, Alessandra [1 ]
Maranhao, Priscila A. [1 ]
Coelho de Souza, Maria das Gracas [1 ,2 ]
Panazzolo, Diogo G. [1 ]
Nogueira Neto, Jose Firmino [3 ]
Bouskela, Eliete [2 ]
Kraemer-Aguiar, Luiz Guilherme [2 ,4 ]
机构
[1] Univ Estado Rio De Janeiro, Fac Med Sci, Postgrad Program Clin & Expt Physiopathol FISCLIN, BR-20550013 Rio De Janeiro, RJ, Brazil
[2] Univ Estado Rio De Janeiro, Biomed Ctr, Lab Clin & Expt Res Vasc Biol BioVasc, BR-20550013 Rio De Janeiro, RJ, Brazil
[3] Univ Estado Rio De Janeiro, Policlin Piquet Carneiro, Lipids Lab Lablip, BR-20550003 Rio De Janeiro, RJ, Brazil
[4] Univ Estado Rio De Janeiro, Fac Med Sci, Dept Internal Med, Obes Unit,Policlin Piquet Carneiro, BR-20550030 Rio De Janeiro, RJ, Brazil
关键词
diabetes; microcirculation; metformin; vildagliptin; postprandial; CARDIOVASCULAR-DISEASE; ENDOTHELIAL FUNCTION; METABOLIC SYNDROME; GLUCOSE; CHOLESTEROL; INSULIN; ASSOCIATION; DYSFUNCTION; PLASMA; GLP-1;
D O I
10.3390/jcm9103228
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Type 2 diabetes mellitus and obesity are both related to endothelial dysfunction. Postprandial lipemia is a cardiovascular risk. Notably, it is known that a high-fat diet may elicit microvascular dysfunction, even in healthy subjects. Since anti-diabetic drugs have different mechanisms of action and also distinct vascular benefits, we aimed to compare the results of two anti-diabetic drugs after the intake of a lipid-rich meal on microcirculation in patients with type 2 diabetes and obesity. In parallel, we also investigated the metabolic profile, oxidative stress, inflammation, plasma viscosity, and some gastrointestinal peptides. Subjects/Methods: We included 38 drug-naive patients, all women aged between 19 and 50 years, with BMI >= 30 kg/m(2). We performed endothelial measurements and collected samples before (fasting) and after the intake of a lipid-rich meal at 30, 60, 120, and 180 min. Patients were randomized to metformin or vildagliptin, given orally just before the meal. Endothelial function was assessed by videocapillaroscopy and laser-Doppler flowmetry to investigate microvascular reactivity. Besides, we also investigated plasma viscosity, inflammatory and oxidative stress biomarkers, gastrointestinal peptides, and metabolic profile in all time points. Results: No differences at baseline were noted between groups. Vildagliptin increased glucagon-like peptide-1 compared to metformin. Paired comparisons showed that, during the postprandial period, vildagliptin significantly changed levels of insulin and glucagon-like peptide-1, and also the dipeptidyl peptidase-4 activity, while metformin had effects on plasma glucose solely. Metformin use during the test meal promoted an increase in functional capillary density, while vildagliptin kept non-nutritive microvascular blood flow and vasomotion unchanged. Conclusions: After the intake of a lipid-rich meal, the use of vildagliptin preserved postprandial non-nutritive microflow and vasomotion, while metformin increased capillary recruitment, suggesting protective and different mechanisms of action on microcirculation.
引用
收藏
页码:1 / 11
页数:11
相关论文
共 50 条
  • [1] The role of glucagon-like peptide 1 in the postprandial effects of metformin in type 2 diabetes: a randomized crossover trial
    Hansen, Laura S.
    Gasbjerg, Laerke S.
    Bronden, Andreas
    Dalsgaard, Niels B.
    Bahne, Emilie
    Stensen, Signe
    Hellmann, Pernille H.
    Rehfeld, Jens F.
    Hartmann, Bolette
    Wewer Albrechtsen, Nicolai J.
    Holst, Jens J.
    Vilsboll, Tina
    Knop, Filip K.
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2024, 191 (02) : 192 - 203
  • [2] Effect of metformin on arginine and dimethylarginines in patients with advanced type 2 diabetes: A post hoc analysis of a randomized trial
    Top, Wiebe M. C.
    Lehert, Philippe
    Schalkwijk, Casper G.
    Stehouwer, Coen D. A.
    Kooy, Adriaan
    DIABETES OBESITY & METABOLISM, 2022, 24 (10) : 1983 - 1988
  • [3] A randomized controlled clinical trial of combination therapy for type 2 diabetes by vildagliptin, metformin, and α-glucosidase inhibitor
    Wang, Qiong
    Su, Yong
    Lv, Lifang
    INTERNATIONAL JOURNAL OF DIABETES IN DEVELOPING COUNTRIES, 2016, 36 (04) : 420 - 425
  • [4] Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial
    Schweizer, A.
    Dejager, S.
    Bosi, E.
    DIABETES OBESITY & METABOLISM, 2009, 11 (08) : 804 - 812
  • [5] A randomized controlled clinical trial of combination therapy for type 2 diabetes by vildagliptin, metformin, and α-glucosidase inhibitor
    Qiong Wang
    Yong Su
    Lifang Lv
    International Journal of Diabetes in Developing Countries, 2016, 36 : 420 - 425
  • [6] RETRACTED: Effect of rosuvastatin on fasting and postprandial endothelial biomarker levels and microvascular reactivity in patients with type 2 diabetes and dyslipidemia: a preliminary report (Retracted Article)
    Kim, Kyoung Min
    Jung, Kyong Yeun
    Yun, Han Mi
    Lee, Seo Young
    Oh, Tae Jung
    Jang, Hak Chul
    Lim, Soo
    CARDIOVASCULAR DIABETOLOGY, 2017, 16
  • [7] A randomized controlled clinical trial of vildagliptin plus metformin combination therapy in patients with type II diabetes mellitus
    Su, Yong
    Su, Ya-Li
    Lv, Li-Fang
    Wang, Li-Min
    Li, Quan-Zhong
    Zhao, Zhi-Gang
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2014, 7 (04) : 799 - 803
  • [8] Effects of a liquid high-fat meal on postprandial lipid metabolism in type 2 diabetic patients with abdominal obesity
    Wang, Feng
    Lu, Huixia
    Liu, Fukang
    Cai, Huizhen
    Song, Zhixiu
    Guo, Fei
    Xie, Yulan
    Shu, Guofang
    Sun, Guiju
    NUTRITION & METABOLISM, 2017, 14
  • [9] Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes
    Matikainen, N.
    Manttari, S.
    Schweizer, A.
    Ulvestad, A.
    Mills, D.
    Dunning, B. E.
    Foley, J. E.
    Taskinen, M. -R.
    DIABETOLOGIA, 2006, 49 (09) : 2049 - 2057
  • [10] The effect of vildagliptin versus metformin on hepatic steatosis in type 2 diabetic patients: a randomized controlled trial
    Mohamed, Asmaa S.
    Ahmad, Hosam M.
    Sharawy, Mohammed A.
    Kamel, Fatma M. M.
    BMC PHARMACOLOGY & TOXICOLOGY, 2024, 25 (01)